ClinicalTrials.gg
Active, not recruitingNCT07181083Updated Sep 18, 2025

AI-Based Prediction Model for Iliofemoral DVT Thrombolysis

An observational study in Deep Vein Thrombosis of the Lower Extremities, sponsored by Rajaie Cardiovascular Medical and Research Center. Active, not recruiting at 1 site in Iran. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Rajaie Cardiovascular Medical and Research Center · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

This prospective single-arm cohort study aims to develop an AI-powered prediction model for treatment outcomes in patients with acute extensive iliofemoral deep vein thrombosis (IF-DVT) undergoing stent-free pharmacomechanical thrombolysis. The study addresses the current lack of validated tools for patient selection and outcome prediction in catheter-directed interventions for proximal DVT.

Thirty consecutive adult patients with MRV-confirmed acute IF-DVT will undergo pharmacomechanical thrombolysis using the AngioJet ZelanteDVT system with adjunctive rtPA administration.

The primary objective is to develop a convolutional neural network (CNN) trained on serial MRV imaging data to predict three-month venous recanalization success. MRV acquisitions occur at baseline, predischarge, and three-month follow-up. Ground truth segmentation will be performed by an experienced radiologist using 3D Slicer, with semi-automated propagation across the dataset. Feature extraction will include geometric metrics, radiomic texture analysis, and morphological characteristics of both thrombus and vessel architecture.

Secondary endpoints include acute kidney injury incidence (a significant concern with rheolytic thrombectomy due to hemolysis-induced nephrotoxicity), post-thrombotic syndrome development assessed via Villalta scoring, and various safety outcomes including major bleeding per ISTH criteria.

The study protocol incorporates rigorous monitoring for AKI using KDIGO criteria, with systematic evaluation of renal function, hemolysis markers, and electrolyte balance. Hydration protocols and nephroprotective measures will be standardized, though specific strategies require clarification from the nephrology team.

This research addresses critical gaps in evidence-based patient selection for invasive DVT treatment, particularly following the mixed results of the ATTRACT trial. The AI prediction model could enable personalized treatment decisions, potentially improving the risk-benefit ratio of pharmacomechanical interventions while reducing unnecessary procedures in patients unlikely to benefit.

02

Conditions studied

  • Deep Vein Thrombosis of the Lower Extremities

Keywords

  • Deep vein thrombosis
  • Prediction model
  • Iliofemoral vein
  • Pharmacomechanical thrombolysis
  • Magnetic resonance venography
  • Acute kidney injury
03

In context

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

This study's enrollment of 30 is below the median of 301 across 274 observational studies indexed under Venous Thrombosis.

Browse Venous Thrombosis studies →

Lead sponsor

Rajaie Cardiovascular Medical and Research Center is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be drawn from adult patients aged 18 years and older of both sexes presenting to the Rajaie Cardiovascular Medical and Research Institute, a tertiary referral cardiovascular center in Tehran, Iran, with acute symptomatic iliofemoral deep vein thrombosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All consecutive adult (≥18 years) patients with an MRV-based diagnosis of acute IF- DVT
  • Symptomatic patients with severe pain and\or leg swelling more than 5 cm
  • Willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Previous history of VTE
  • Presence of DVT syndrome for more than 21 days
  • Terminal systemic disease requiring palliative treatment
  • Active bleeding
  • History of hemorrhagic stroke
  • Major fibrinolytic
  • Any hereditary coagulopathy disorders
  • Patients with baseline renal dysfunction with an estimated (eGFR) of \< 60 ml/min/1.73m2 due to Cockroft-Gault formula based on the creatinine level at the time of admission
  • Having any underlying condition that makes the patient unsuitable for MRV and/or rheolytic thrombectomy procedure (e.g., allergy to contrast agent, claustrophobia)
  • Having any underlying disabling condition that necessitates a prolonged complete bed rest prohibiting early ambulation
  • Low-quality MRV imaging or motion artifact (exclusion criteria for the imaging sub-studies)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Extensive iliofemoral DVT

    Patients with extensive ioliofemoral DVT candidate for pharmaco-mechanical thrombectomy

    Device: Rheolytic thrombectomy

Interventions

  • DeviceRheolytic thrombectomy

    Rheolytic thrombectomy via AngioJet ZelanteDVTTM Catheter (Boston Scientific Co., USA).

06

What researchers measure

Primary outcomes

  1. During the procedure

    The extent of venous recanalization after stent-free pharmacomechanical thrombolysis as assessed by magnetic resonance venography at three months post-procedure. Recanalization will be graded as: Grade 0 (no flow/complete occlusion), Grade 1 (minimal flow with ≤25% lumen patency), Grade 2 (partial flow with 26-75% patency), or Grade 3 (near-complete flow with \>75% patency). Treatment success is defined as achieving Grade 2 or 3 recanalization.

    Time frame: 3 months post-procedure

Secondary outcomes

  1. MRV-based Predischarge Venous Recanalization

    The extent of venous recanalization in the acute phase after stent-free pharmacomechanical thrombolysis as measured by magnetic resonance venography, classified as complete (\>90% clearance), nearly complete (50-90% clearance), or partial (\<50% resolution)

    Time frame: At hospital discharge (typically 3-7 days post-procedure)

  2. At hospital discharge (typically 3-7 days post-procedure)

    Quantified thrombus volume reduction from baseline to three-month follow-up as measured by magnetic resonance venography, with meaningful reduction defined as ≥50% volume decrease

    Time frame: 3 months post-procedure

  3. MRV-based Predischarge Percentage Reduction in Thrombus Volume

    Quantified thrombus volume reduction from baseline to hospital discharge as measured by magnetic resonance venography, with meaningful reduction defined as ≥50% volume decrease

    Time frame: At hospital discharge (typically 3-7 days post-procedure)

  4. Postprocedural Acute Kidney Injury Occurrence

    Development of acute kidney injury during hospitalization based on KDIGO criteria: ≥0.3 mg/dL increase in serum creatinine within 48 hours, ≥1.5x baseline creatinine increase, or urine output \<0.5 mL/kg/h for 6 hours.

    Time frame: During index hospitalization (typically 3-7 days)

  5. Need for New Renal Replacement Therapy

    Requirement for initiation of any form of renal replacement therapy (hemodialysis, continuous veno-venous hemofiltration, peritoneal dialysis) due to acute kidney injury in patients without previous dialysis history.

    Time frame: During index hospitalization (typically 3-7 days)

  6. Postprocedural Oliguria or Anuria

    Development of oliguria (urine output \<0.5 mL/kg/hour) or anuria (urine output \<50 mL/day) during the index hospitalization period.

    Time frame: During index hospitalization (typically 3-7 days)

  7. Postprocedural Hyperkalemia

    Elevated serum potassium concentration above normal limits (\>5.0-5.5 mEq/L) during the index hospitalization period.

    Time frame: During index hospitalization (typically 3-7 days)

  8. Postprocedural Gross Hematuria

    Presence of visible blood in urine detected by visual inspection or urine testing during the index hospitalization period.

    Time frame: During index hospitalization (typically 3-7 days)

  9. Major Bleeding Events

    Major bleeding according to International Society of Thrombosis and Haemostasis (ISTH) definition: fatal bleeding, bleeding in critical organs, or bleeding causing ≥2.0 g/dL hemoglobin decrease or requiring ≥2 units red blood cell transfusion.

    Time frame: During index hospitalization (typically 3-7 days)

  10. Three-month Recurrent Venous Thromboembolism

    Objectively confirmed recurrent symptomatic venous thromboembolism (deep vein thrombosis or pulmonary embolism) during the three-month follow-up period.

    Time frame: 3 months post-procedure

  11. Three-month Post-thrombotic Syndrome Incidence

    Development of post-thrombotic syndrome defined as Villalta score ≥5, assessed through standardized evaluation of symptoms (pain, cramps, heaviness, paresthesia, pruritus) and clinical signs (edema, induration, hyperpigmentation, redness, venous ectasia, calf pain on compression).

    Time frame: 3 months post-procedure

  12. Three-month Post-thrombotic Syndrome Severity

    Severity classification of post-thrombotic syndrome using Villalta score: mild (5-9), moderate (10-14), or severe (≥15 or venous ulceration).

    Time frame: 3 months post-procedure

  13. In-hospital All-cause Mortality

    Death from any cause during the index hospitalization period.

    Time frame: During index hospitalization (typically 3-7 days)

  14. Three-month All-cause Mortality

    Death from any cause during the three-month follow-up period.

    Time frame: 3 months post-procedure

  15. Technical Success Rate

    Successful placement of the AngioJet device catheter and initiation of the thrombectomy procedure as intended per protocol.

    Time frame: During the procedure

07

Study locations

1 site
  • Rajaie Cardiovascular Medical and Research Institute
    Tehran, Tehran Province 1995614331, Iran
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.

Of 103 non-industry observational studies under Venous Thrombosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 99. This study's planned 15 months is below that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartActual
Jul 1, 2024
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07181083
Lead sponsor
Rajaie Cardiovascular Medical and Research Center
Responsible party
Parham Sadeghipour (Doctor, Rajaie Cardiovascular Medical and Research Center) — Principal investigator
First posted
Sep 18, 2025
Start date
Jul 1, 2024
Primary completion
Oct 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Sep 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion